jRCT ロゴ

臨床研究等提出・公開システム

Top

Japanese

Jan. 30, 2012

Dec. 17, 2018

jRCT2080221706

Phase I trial of YHI-1003 Added to the Combination of Bortezomib and Dexamethasone in Multiple Myeloma Patients Previously Treated with Bortezomib

Phase I trial of YHI-1003 plus Bortezomib and Dexamethasone

Yakult Honsha Co., Ltd.

TEL: +81-3-5550-8968

18

Interventional

open-label, multicenter trial

1

(1)Patients were previously diagnosed with multiple myeloma
(2)Patients must have relapsed after their last dose of bortezomib-based therapy
(3)Patients must have received 1 to 4-myeloma therapies
(4)ECOG performance status (PS) :0-2

(1)Patients with uncontrolled intercurrent illness
(2)Female patients who are pregnant or lactating
(3)Patients with non-secretory multiple myeloma

20age old over
No limit

Both

Relapsed Multiple Myeloma previously treated with Bortezomib

investigational material(s)
Generic name etc : YHI-1003
INN of investigational material : Perifosine
Therapeutic category code : 429 Other antitumor agents
Dosage and Administration for Investigational material : oral

safety
CTCAE v3.0

efficacy and pharmacokinetic profile

Yakult Honsha Co., Ltd.

JapicCTI-121748

History of Changes

No Publication date
5 Dec. 17, 2018 (this page) Changes
4 Mar. 12, 2013 Detail Changes
3 Mar. 12, 2013 Detail Changes
2 Mar. 09, 2012 Detail Changes
1 Jan. 30, 2012 Detail